MQX‐503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon:A randomized, controlled trial
Naomi F. Rothfield(University of Connecticut), Fredrick M. Wigey, Lee Shapiro(Albany Medical Center Hospital), Mary Ellen Csuka(Medical College of Wisconsin), Bashar Kahaleh(University of Toledo), David Fiorentino(Stanford University), Barry L. Gruber(State University of New York), Nadera Sweiss(University of Illinois Chicago), Robert W. Simms(Dartmouth–Hitchcock Medical Center), A Scheja(Ospedali Riuniti Umberto I), Sangeeta Sule, Edwin Smith(Medical University of South Carolina), Lorinda Chung(Stanford University), Janet E. Pope, Ariane Herrick, Jill; id_orcid 0000-0001-8280-6689 Belch, Paul Emery, Maureen Mayes, Vivien Hsu, Virginia Steen, Murray Baron, Richard Martin, Joseph C. Shanahan(Duke University), Christopher Denton, David H. Collier(Amgen (United States))
Discovery Research Portal (University of Dundee)
September 1, 2008
Cited by 0
Related Papers
The 1982 revised criteria for the classification of systemic lupus erythematosus
|Arthritis & Rheumatism|1982|14.6k
Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI.
|Proceedings of the National Academy of Sciences|1991|752
Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma
|New England Journal of Medicine|2018|598
The WASOG Sarcoidosis Organ Assessment Instrument: An update of a previous clinical tool.
|PubMed|2014|505
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial
|Annals of the Rheumatic Diseases|2010|503